Abstract:Prefibrotic stimuli overactivate MELTT3 and m6A modifications in TECs and renal tissues. Upregulated METTL3 enhances the m6A modification of EVL mRNA through an IGF2BP2‐dependent mechanism. EVL binds to Smad7 to attenuate its inhibition of TGF‐β1/Smad3, which conversely promotes renal fibrosis. Inhibition of METTL3 and the METTL3/EVL m6A axis markedly alleviates renal fibrosis. Isoforsythiaside is a potential antifibrotic agent that inhibits the METTL3/EVL m6A axis. Background N6‐methyladenosine (m6A) is of great importance in renal physiology and disease progression, but its function and mechanism in renal fibrosis remain to be comprehensively and extensively explored. Hence, this study will explore the function and potential mechanism of critical regulator‐mediated m6A modification during renal fibrosis and thereby explore promising anti‐renal fibrosis agents. Methods Renal tissues from humans and mice as well as HK‐2 cells were used as research subjects. The profiles of m6A modification and regulators in renal fibrosis were analysed at the protein and RNA levels using Western blotting, quantitative real‐time polymerase chain reaction and other methods. Methylation RNA immunoprecipitation sequencing and RNA sequencing coupled with methyltransferase‐like 3 (METTL3) conditional knockout were used to explore the function of METTL3 and potential targets. Gene silencing and overexpression combined with RNA immunoprecipitation were performed to investigate the underlying mechanism by which METTL3 regulates the Ena/VASP‐like (EVL) m6A modification that promotes renal fibrosis. Molecular docking and virtual screening with in vitro and in vivo experiments were applied to screen promising traditional Chinese medicine (TCM) monomers and explore their mechanism of regulating the METTL3/EVL m6A axis and anti‐renal fibrosis. Results METTL3 and m6A modifications were hyperactivated in both the tubular region of fibrotic kidneys and HK‐2 cells. Upregulated METTL3 enhanced the m6A modification of EVL mRNA to improve its stability and expression in an insulin‐like growth factor 2 mRNA‐binding protein 2 (IGF2BP2)‐dependent manner. Highly expressed EVL binding to Smad7 abrogated the Smad7‐induced suppression of transforming growth factor‐β (TGF‐β1)/Smad3 signal transduction, which conversely facilitated renal fibrosis progression. Molecular docking and virtual screening based on the structure of METTL3 identified a TCM monomer named isoforsythiaside, which inhibited METTL3 activity together with the METTL3/EVL m6A axis to exert anti‐renal fibrosis effects. Conclusions Collectively, the overactivated METTL3/EVL m6A axis is a potential target for renal fibrosis therapy, and the pharmacological inhibition of METTL3 activity by isoforsythiaside suggests that it is a promising anti‐renal fibrosis agent.

Myricanol represses renal fibrosis by activating TFAM and ZNRF1 to inhibit tubular epithelial cells ferroptosis.

Mitophagy Induced by UMI-77 Preserves Mitochondrial Fitness in Renal Tubular Epithelial Cells and Alleviates Renal Fibrosis

Myricitrin inhibited ferritinophagy-mediated ferroptosis in cisplatin-induced human renal tubular epithelial cell injury

Role of mitochondria in pathogenesis and therapy of renal fibrosis

Myricetin Attenuated Diabetes-Associated Kidney Injuries and Dysfunction Via Regulating Nuclear Factor (erythroid Derived 2)-Like 2 and Nuclear Factor-κB Signaling

Maresin conjugates in tissue regeneration-1 suppresses ferroptosis in septic acute kidney injury

Ethyl Ferulate suppresses Post-Myocardial Infarction Myocardial Fibrosis by Inhibiting Transforming Growth Factor Receptor 1

#2036 Mitochondrial copper overload promotes renal fibrosis via inhibiting pyruvate dehydrogenase activity

MiR-375-3p Promotes Cardiac Fibrosis by Regulating the Ferroptosis Mediated by GPX4

MnTBAP Therapy Attenuates Renal Fibrosis in Mice with 5/6 Nephrectomy

Ferrostatin-1 specifically targets mitochondrial iron-sulfur clusters and aconitase to improve cardiac function in Sirtuin 3 cardiomyocyte knockout mice

Mito-TEMPO Alleviates Renal Fibrosis by Reducing Inflammation, Mitochondrial Dysfunction, and Endoplasmic Reticulum Stress.

Pharmacological Inhibition of STING/TBK1 Signaling Attenuates Myeloid Fibroblast Activation and Macrophage to Myofibroblast Transition in Renal Fibrosis

Demethylzeylasteral protects against renal interstitial fibrosis by attenuating mitochondrial complex I-mediated oxidative stress

Tubular MYDGF Slows Progression of Chronic Kidney Disease by Maintaining Mitochondrial Homeostasis

Ferrostatin-1 Targets Mitochondrial Function to Improve Heart Failure in a Cardiomyocyte-Specific SIRT3 Knockout Mouse Model

XJB-5-131 inhibited ferroptosis in tubular epithelial cells after ischemia-reperfusion injury

Genetic and pharmacological inhibition of METTL3 alleviates renal fibrosis by reducing EVL m6A modification through an IGF2BP2‐dependent mechanism

MCTR1 Intervention Reverses Experimental Lung Fibrosis in Mice

Novel RAS Inhibitor 25-O-methylalisol F Attenuates Epithelial-to-mesenchymal Transition and Tubulo-Interstitial Fibrosis by Selectively Inhibiting TGF-β-mediated Smad3 Phosphorylation.

Myricitrin Alleviates Oxidative Stress-induced Inflammation and Apoptosis and Protects Mice against Diabetic Cardiomyopathy